Huadong Medicine Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Huadong Medicine wird ein jährliches Gewinn- und Umsatzwachstum von 13.2% bzw. 7.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 16.8% betragen.

Wichtige Informationen

13.2%

Wachstumsrate der Gewinne

13.1%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	23.0%
Wachstumsrate der Einnahmen	7.9%
Zukünftige Eigenkapitalrendite	16.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	13 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Apr 21

Recent updates

Investors Aren't Buying Huadong Medicine Co., Ltd's (SZSE:000963) Earnings

Nov 13

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Sep 23

Earnings Working Against Huadong Medicine Co., Ltd's (SZSE:000963) Share Price

Aug 05

Huadong Medicine (SZSE:000963) Seems To Use Debt Rather Sparingly

Jun 28

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Jun 10

Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Apr 21

Market Cool On Huadong Medicine Co., Ltd's (SZSE:000963) Earnings

Apr 08

Is Huadong Medicine (SZSE:000963) A Risky Investment?

Mar 16

Gewinn- und Umsatzwachstumsprognosen

SZSE:000963 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	50,260	4,280	3,240	4,786	12
12/31/2025	46,834	3,908	2,721	4,230	14
12/31/2024	43,247	3,292	2,615	3,942	14
9/30/2024	41,707	3,212	2,609	4,186	N/A
6/30/2024	41,204	3,101	2,516	4,183	N/A
3/31/2024	40,920	2,946	2,010	3,691	N/A
12/31/2023	40,624	2,839	2,323	3,929	N/A
9/30/2023	40,251	2,707	1,996	3,311	N/A
6/30/2023	39,902	2,592	2,932	4,119	N/A
3/31/2023	38,897	2,550	998	2,396	N/A
1/1/2023	37,715	2,499	1,189	2,382	N/A
9/30/2022	36,494	2,388	1,266	2,384	N/A
6/30/2022	35,582	2,342	696	1,715	N/A
3/31/2022	34,599	2,248	1,897	2,607	N/A
1/1/2022	34,563	2,302	2,351	3,170	N/A
9/30/2021	34,110	2,324	2,468	3,616	N/A
6/30/2021	34,202	2,389	2,540	3,894	N/A
3/31/2021	33,982	2,431	1,986	3,495	N/A
12/31/2020	33,683	2,820	1,938	3,411	N/A
9/30/2020	33,319	2,991	1,669	2,994	N/A
6/30/2020	33,858	2,948	1,036	2,294	N/A
3/31/2020	34,339	3,053	1,345	2,654	N/A
12/31/2019	35,446	2,813	648	2,002	N/A
9/30/2019	35,087	2,671	469	1,537	N/A
6/30/2019	33,587	2,570	878	1,932	N/A
3/31/2019	32,532	2,515	1,225	2,163	N/A
12/31/2018	30,663	2,267	1,163	2,039	N/A
9/30/2018	29,585	2,099	2,215	2,946	N/A
6/30/2018	29,066	2,031	N/A	2,455	N/A
3/31/2018	28,519	1,895	N/A	1,985	N/A
12/31/2017	27,832	1,780	N/A	1,661	N/A
9/30/2017	27,911	1,740	N/A	1,009	N/A
6/30/2017	27,227	1,665	N/A	612	N/A
3/31/2017	26,363	1,556	N/A	1,085	N/A
12/31/2016	25,380	1,447	N/A	1,347	N/A
9/30/2016	24,491	1,365	N/A	957	N/A
6/30/2016	23,588	1,253	N/A	796	N/A
3/31/2016	22,682	1,188	N/A	387	N/A
12/31/2015	21,727	1,097	N/A	659	N/A
9/30/2015	20,923	1,136	N/A	545	N/A
6/30/2015	20,220	1,034	N/A	1,144	N/A
3/31/2015	19,656	899	N/A	857	N/A
12/31/2014	18,947	757	N/A	741	N/A
9/30/2014	18,208	655	N/A	1,349	N/A
6/30/2014	17,724	631	N/A	624	N/A
3/31/2014	17,237	617	N/A	395	N/A
12/31/2013	16,718	575	N/A	477	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 000963Das prognostizierte Gewinnwachstum (13.2% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 000963Die Erträge des Unternehmens (13.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (26% pro Jahr).

Hohe Wachstumserträge: 000963Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 000963Die Einnahmen des Unternehmens (7.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.9% pro Jahr).

Hohe Wachstumseinnahmen: 000963Die Einnahmen des Unternehmens (7.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 000963Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (16.8%).

Huadong Medicine Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Price target increased to CN¥49.08

Price target increased to CN¥43.06

Price target decreased to CN¥38.92

Price target increased to CN¥45.53

Price target increased to CN¥38.24

Recent updates

Investors Aren't Buying Huadong Medicine Co., Ltd's (SZSE:000963) Earnings

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Huadong Medicine Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Huadong Medicine Co., Ltd Announces Interim Profit Distribution Plan to Be Implemented on A Shares for the Year 2024, Payable on 20 September 2024

Huadong Medicine Co., Ltd. Announces Interim Dividend for the First Half of 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Working Against Huadong Medicine Co., Ltd's (SZSE:000963) Share Price

Huadong Medicine Co., Ltd to Report First Half, 2024 Results on Aug 16, 2024

Huadong Medicine (SZSE:000963) Seems To Use Debt Rather Sparingly

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Huadong Medicine Co., Ltd Approves Cash Dividend

High number of new directors

Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Huadong Medicine Co., Ltd, Annual General Meeting, May 08, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Market Cool On Huadong Medicine Co., Ltd's (SZSE:000963) Earnings

Huadong Medicine Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Is Huadong Medicine (SZSE:000963) A Risky Investment?

Huadong Medicine Co., Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024

Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm

Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Huadong Medicine Co., Ltd to Report First Half, 2023 Results on Aug 16, 2023

Huadong Medicine Co., Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 14 June 2023

Huadong Medicine Co., Ltd Approves Cash Dividend for 2022

Full year 2022 earnings: EPS misses analyst expectations

Price target increased to CN¥49.08

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥43.06

Huadong Medicine Co., Ltd Approves Board Appointments

Huadong Medicine Co., Ltd, Annual General Meeting, Jun 01, 2022

Price target decreased to CN¥38.92

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.38 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.33 in 2Q 2020)

Price target increased to CN¥45.53

Investor sentiment deteriorated over the past week

Huadong Medicine Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09 June 2021

Huadong Medicine Co., Ltd Announces Dividend for 2020

Investor sentiment deteriorated over the past week

Price target increased to CN¥38.24

Full year 2020 earnings released: EPS CN¥1.61 (vs CN¥1.61 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Huadong Medicine Co., Ltd to Report Fiscal Year 2020 Results on Apr 21, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target raised to CN¥34.09

New 90-day low: CN¥26.05

Price target raised to CN¥33.50

Market bids up stock over the past week

New 90-day high: CN¥30.35

Third-quarter earnings released: Revenue and earnings miss expectations

Third quarter earnings released

Huadong Medicine Co., Ltd to Report Q3, 2020 Results on Oct 27, 2020

First half earnings released

Huadong Medicine Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite